RGA Bears Retreat After Earnings — Options Tell a Different Story
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Reinsurance Group of America just printed a sharp short-side capitulation. Short interest dropped 31% in a single week. Yet the options market is pushing back.
Shorts Exit at Speed
RGA's short interest fell to 1.22% of free float as of August 11. That's down from roughly 1.78% a week prior. It marks the fastest weekly retreat since late July. The stock gained 3.6% over the same period, rising to $244.65.
This is a clean post-earnings unwind. RGA reported Q2 on August 6 and posted a +4.2% one-day move. Bears who held into the print appear to have closed out quickly. Short interest is now at its lowest level in the 30-day history of this data.
Borrow conditions remain completely unconstrained. Availability is effectively unlimited — 64.8 million shares are available to borrow against fewer than 805,000 actually borrowed. Cost to borrow sits at 0.45%, near the low end of its recent range. There is no friction on the short side at all.
Options Diverge From the Tape
That's what makes the options signal worth watching. The put/call ratio sits at 0.42, nearly 2.0 standard deviations above its 20-day mean of 0.19.
This is not a small drift. For most of July, RGA's PCR sat below 0.10 — reflecting almost no hedging demand. The ratio began climbing around August 7, the day after earnings, and has held elevated since. Noted in the prior coverage on August 7: the PCR was already ticking higher at that point. It has continued.
The divergence is clear. Shorts are covering. Options buyers are adding puts. Two groups, reading the same post-earnings tape, drawing opposite conclusions.
Analysts Stay Constructive
The analyst community has not wavered. JP Morgan raised its target to $293 from $286 on August 11, maintaining Overweight. Barclays raised to $290 from $278 on August 7. The consensus mean target stands at $266.89 — roughly 9% above the current price of $244.65.
Five of the last eight analyst actions since early July have been target raises. No downgrades. The institutional holder base is also stable, with BlackRock holding 10.4% and FMR at 8.9% as of July 31.
The ORTEX short score has dropped to 29.8 from 32.2 a week ago — confirming the reduced short-side pressure in the data.
What to Watch
The PCR at 0.42 stands roughly 2 standard deviations above the recent norm. Whether that put activity is protective hedging by longs who rode the earnings rally — or genuine directional bearishness — will likely clarify as the position matures. Next earnings are not due until November 5.
- Short Interest % FF: 1.22% (down 31.5% week-on-week)
- Put/Call Ratio: 0.42 vs. 20-day mean of 0.19 (z-score: ~1.94)
- Cost to Borrow: 0.45%
- Availability: effectively unconstrained
- Stock price: $244.65, +3.6% on the week
- Consensus target: $266.89 (~9% upside)
- JP Morgan target (Aug 11): $293 (Overweight)
Stocks in this article
See the live data behind this article on ORTEX.
Open RGA on ORTEX →How this article was generated
- Generated
- 12 Aug 2026, 16:20
- Data as of
- 12 Aug 2026, 16:17
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.